August 28, 2025

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

August 22, 2025

New CT Score Tracks Pneumonia Stage Progression

Researchers validate a visual CT scoring system designed to improve classification of pneumonia-related lung changes in clinical and research settings.

Conexiant

August 21, 2025

Medical Oddities: Puberty’s Hidden Fine Print

Puberty timing, feline brains, tea habits, sweat patches, and stings unite in this week’s medical grab bag.

Conexiant

August 21, 2025

Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?

Rechallenge with the HER2-directed antibody-drug conjugate after grade 1 interstitial lung disease appeared to be safe in a diverse real-world population, including many patients with breast cancer, a...

The ASCO Post

August 11, 2025

Why Turning 26 Jeopardizes Health Coverage

A growing number of young Americans lose affordable health insurance at age 26, facing complex Affordable Care Act marketplaces, rising costs, and limited coverage options.

KFF Health News

August 04, 2025

Daily Microplastic Inhalation Rates Estimated in Study

Using Raman spectroscopy and based on extrapolated concentrations measured in residential and car cabin environments, researchers found that adults may inhale up to 68,000 microplastic particles daily from indoor air.

Conexiant

August 01, 2025

Pulmonary Embolism Following Pelvic Glue Procedure

Pulmonary glue embolism should be suspected when patients develop respiratory symptoms following radiologic embolization.

Conexiant

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant